A citation-based method for searching scientific literature

Yi-Long Wu, James Chih-Hsin Yang, Dong-Wan Kim, Shun Lu, Jianying Zhou, Takashi Seto, Jin-Ji Yang, Noboru Yamamoto, Myung-Ju Ahn, Toshiaki Takahashi, Takeharu Yamanaka, Allison Kemner, Debasish Roychowdhury, Jolanda Paolini, Tiziana Usari, Keith D Wilner, Koichi Goto. J Clin Oncol 2018
Times Cited: 129



Alice T Shaw, Sai-Hong I Ou, Yung-Jue Bang, D Ross Camidge, Benjamin J Solomon, Ravi Salgia, Gregory J Riely, Marileila Varella-Garcia, Geoffrey I Shapiro, Daniel B Costa, Robert C Doebele, Long Phi Le, Zongli Zheng, Weiwei Tan, Patricia Stephenson, S Martin Shreeve, Lesley M Tye, James G Christensen, Keith D Wilner, Jeffrey W Clark, A John Iafrate. N Engl J Med 2014
Times Cited: 1123




List of shared articles



Times cited

ROS1-dependent cancers - biology, diagnostics and therapeutics.
Alexander Drilon, Chelsea Jenkins, Sudarshan Iyer, Adam Schoenfeld, Clare Keddy, Monika A Davare. Nat Rev Clin Oncol 2021
22


Acquired MET D1228N Mutations Mediate Crizotinib Resistance in Lung Adenocarcinoma with ROS1 Fusion: A Case Report.
Yu Wang, Zheng Chen, Xiao Han, Jiamei Li, Honglin Guo, Junping Shi. Oncologist 2021
4


Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer.
Marie-Julie Nokin, Chiara Ambrogio, Ernest Nadal, David Santamaria. Trends Cancer 2021
3

Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer.
Jessica J Lin, Noura J Choudhury, Satoshi Yoda, Viola W Zhu, Ted W Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R Digumarthy, Charlotte Lee, Andrew Do,[...]. Clin Cancer Res 2021
2

Uncommon targets in non-small cell lung cancer: Everyone wants a slice of cake.
Alessandro De Toma, Giuseppe Lo Russo, Diego Signorelli, Filippo Pagani, Giovanni Randon, Giulia Galli, Arsela Prelaj, Roberto Ferrara, Claudia Proto, Monica Ganzinelli,[...]. Crit Rev Oncol Hematol 2021
2

Oncogenic driver mutations in non-small cell lung cancer: Past, present and future.
Mathieu Chevallier, Maxime Borgeaud, Alfredo Addeo, Alex Friedlaender. World J Clin Oncol 2021
4

[NSCLC and new oncogenic mutations: Diagnosis and perspectives].
C Basse, A Swalduz, A Mc Leer, D Moro-Sibilot, J Remon, N Girard. Rev Mal Respir 2021
0

Treatment of Rare Mutations in Patients with Lung Cancer.
Tarek Taha, Rasha Khoury, Ronen Brenner, Haitam Nasrallah, Irena Shofaniyeh, Samih Yousef, Abed Agbarya. Biomedicines 2021
0

ROS1 Targeted Therapies: Current Status.
Christine M Azelby, Mandy R Sakamoto, Daniel W Bowles. Curr Oncol Rep 2021
2

SHP2 Inhibition Enhances the Effects of Tyrosine Kinase Inhibitors in Preclinical Models of Treatment-naïve ALK-, ROS1-, or EGFR-altered Non-small Cell Lung Cancer.
Hirohisa Kano, Eiki Ichihara, Hiromi Watanabe, Kazuya Nishii, Chihiro Ando, Takamasa Nakasuka, Kiichiro Ninomiya, Yuka Kato, Toshio Kubo, Kammei Rai,[...]. Mol Cancer Ther 2021
1

Peripheral Lung Squamous Carcinoma With ROS1 Rearrangement Sensitive to Crizotinib: A Case Report.
Guangdie Yang, Jie Wang, Yinan Yao, Jun Zhao, Zheyan Yu, Qiqi Gao, Jiani Ye, Wenjiang Ma. Front Oncol 2021
0

Lung cancer.
Alesha A Thai, Benjamin J Solomon, Lecia V Sequist, Justin F Gainor, Rebecca S Heist. Lancet 2021
8

The rapidly evolving landscape of novel targeted therapies in advanced non-small cell lung cancer.
Barbara Melosky, Paul Wheatley-Price, Rosalyn A Juergens, Adrian Sacher, Natasha B Leighl, Ming-Sound Tsao, Parneet Cheema, Stephanie Snow, Geoffrey Liu, Paul B Card,[...]. Lung Cancer 2021
2

Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study.
Yongchang Zhang, Xiangyu Zhang, Ruiguang Zhang, Qinqin Xu, Haiyan Yang, Analyn Lizaso, Chunwei Xu, Jun Liu, Wenxian Wang, Sai-Hong Ignatius Ou,[...]. BMC Med 2021
0

Entrectinib for ROS1-rearranged non-small cell lung cancer after crizotinib-induced interstitial lung disease: A case report.
Mai Tanimura, Nobutaka Kataoka, Yusuke Kunimatsu, Rei Tsutsumi, Izumi Sato, Takayuki Nakano, Keiko Tanimura, Takayuki Takeda. Respirol Case Rep 2021
0

Cost-effectiveness analysis of first-line treatment with crizotinib in ROS1-rearranged advanced non-small cell lung cancer (NSCLC) in Canada.
Jaclyn M Beca, Shaun Walsh, Kaiwan Raza, Stacey Hubay, Andrew Robinson, Elena Mow, James Keech, Kelvin K W Chan. BMC Cancer 2021
0


Recent advances in lung cancer genomics: Application in targeted therapy.
Neha Pathak, Sindhura Chitikela, Prabhat Singh Malik. Adv Genet 2021
1

Deepening the Knowledge of ROS1 Rearrangements in Non-Small Cell Lung Cancer: Diagnosis, Treatment, Resistance and Concomitant Alterations.
Giorgia Guaitoli, Federica Bertolini, Stefania Bettelli, Samantha Manfredini, Michela Maur, Lucia Trudu, Beatrice Aramini, Valentina Masciale, Giulia Grisendi, Massimo Dominici,[...]. Int J Mol Sci 2021
0

Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.
P Garrido, E Conde, J de Castro, J J Gómez-Román, E Felip, L Pijuan, D Isla, J Sanz, L Paz-Ares, F López-Ríos. Clin Transl Oncol 2020
24

Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer.
Subba R Digumarthy, Dexter P Mendoza, Jessica J Lin, Tianqi Chen, Marguerite M Rooney, Emily Chin, Lecia V Sequist, Jochen K Lennerz, Justin F Gainor, Alice T Shaw. Clin Lung Cancer 2020
12

Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trials.
Alexander Drilon, Salvatore Siena, Rafal Dziadziuszko, Fabrice Barlesi, Matthew G Krebs, Alice T Shaw, Filippo de Braud, Christian Rolfo, Myung-Ju Ahn, Jürgen Wolf,[...]. Lancet Oncol 2020
112

Treatment of advanced non-small-cell lung cancer: The 2019 AIOM (Italian Association of Medical Oncology) clinical practice guidelines.
F Passiglia, S Pilotto, F Facchinetti, L Bertolaccini, M Del Re, R Ferrara, T Franchina, U Malapelle, J Menis, A Passaro,[...]. Crit Rev Oncol Hematol 2020
24

Rapidly Destructive Coxarthrosis as a Potential Side Effect of Crizotinib in a Patient with ROS1-Positive Lung Adenocarcinoma.
Shinkichi Takamori, Takashi Seto, Mikako Jinnouchi, Taro Oba, Masafumi Yamaguchi, Mitsuhiro Takenoyama. Ther Clin Risk Manag 2020
2


Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Haiyan Xu, Quan Zhang, Li Liang, Junling Li, Zhefeng Liu, Weihua Li, Lu Yang, Guangjian Yang, Fei Xu, Jianming Ying,[...]. Cancer Med 2020
6


Entrectinib for the treatment of metastatic NSCLC: safety and efficacy.
Andrea Sartore-Bianchi, Elio Gregory Pizzutilo, Giovanna Marrapese, Federica Tosi, Giulio Cerea, Salvatore Siena. Expert Rev Anticancer Ther 2020
9

ROS1-rearranged Non-small Cell Lung Cancer.
Nicholas P Giustini, Lyudmila Bazhenova. Thorac Surg Clin 2020
2

Miliary lung metastases from ROS1-rearranged lung adenocarcinoma: A case report.
Ryota Otoshi, Akimasa Sekine, Koji Okudela, Takuma Katano, Masato Asaoka, Satoshi Ikeda, Tomohisa Baba, Shigeru Komatsu, Eri Hagiwara, Ogura Takashi. Mol Clin Oncol 2020
1

Clinical activity of brigatinib in ROS1-rearranged non-small cell lung cancer.
E Dudnik, A Agbarya, R Grinberg, A Cyjon, J Bar, M Moskovitz, N Peled. Clin Transl Oncol 2020
1


A novel TJP1-ROS1 fusion in malignant peripheral nerve sheath tumor responding to crizotinib: A case report.
Juming Li, Lingxiang Liu, Qi Zhang, Yumin Huang, Yihong Zhang, Xiaoyan Gan, Siqin Liu, Zhen Yue, Yongzhong Wei. Medicine (Baltimore) 2020
1

Matching-adjusted indirect comparison: entrectinib versus crizotinib in ROS1 fusion-positive non-small cell lung cancer.
Paula Chu, Miranta Antoniou, Mohit K Bhutani, Amine Aziez, Monica Daigl. J Comp Eff Res 2020
2

[Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: A National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology].
Fernando López-Ríos, Luis Paz-Ares, Julián Sanz, Dolores Isla, Lara Pijuan, Enriqueta Felip, José Javier Gómez-Román, Javier de Castro, Esther Conde, Pilar Garrido. Rev Esp Patol 2020
1

Successful Treatment of Patients with Refractory High-Grade Serous Ovarian Cancer with GOPC-ROS1 Fusion Using Crizotinib: A Case Report.
Dapeng Dong, Ge Shen, Yong Da, Ming Zhou, Gang Yang, Mingming Yuan, Rongrong Chen. Oncologist 2020
1

Effectiveness and prognostic factors of first-line crizotinib treatment in patients with ROS1-rearranged non-small cell lung cancer: A multicenter retrospective study.
Jing Zheng, He Cao, Yuping Li, Chuangzhou Rao, Te Zhang, Jiayou Luo, Dongqing Lv, Yanping Zhu, Jianya Zhou, Jianying Zhou. Lung Cancer 2020
3

Cases of ROS1-rearranged lung cancer: when to use crizotinib, entrectinib, lorlatinib, and beyond?
Kartik Sehgal, Andrew J Piper-Vallillo, Hollis Viray, Adeel M Khan, Deepa Rangachari, Daniel B Costa. Precis Cancer Med 2020
8

Efficacy and Safety of Crizotinib in the Treatment of Advanced Non-Small-Cell Lung Cancer with ROS1 Rearrangement or MET Alteration: A Systematic Review and Meta-Analysis.
Huy Gia Vuong, Thu Quynh Nguyen, Hoang Cong Nguyen, Phuoc Truong Nguyen, An Thi Nhat Ho, Lewis Hassell. Target Oncol 2020
5

Molecular and clinicopathological characteristics of ROS1-rearranged non-small-cell lung cancers identified by next-generation sequencing.
Meiying Cui, Yuchen Han, Pan Li, Jianying Zhang, Qiuxiang Ou, Xiaoling Tong, Ruiying Zhao, Nan Dong, Xue Wu, Wencai Li,[...]. Mol Oncol 2020
3

Novel Multitarget Therapies for Lung Cancer and Respiratory Disease.
Masako Yumura, Tatsuya Nagano, Yoshihiro Nishimura. Molecules 2020
6


Identification of a Novel MPRIP-ROS1 Fusion and Clinical Efficacy of Crizotinib in an Advanced Lung Adenocarcinoma Patient: A Case Report.
Yun Shu, Hui Li, Hongjuan Shang, Jun Chen, Xiaoxing Su, Wei Le, Yan Lei, Liming Tao, Cailiang Zou, Wendy Wu. Onco Targets Ther 2020
1

Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies.
Alberto D'Angelo, Navid Sobhani, Robert Chapman, Stefan Bagby, Carlotta Bortoletti, Mirko Traversini, Katia Ferrari, Luca Voltolini, Jacob Darlow, Giandomenico Roviello. Cancers (Basel) 2020
10


Overcoming TKI resistance in fusion-driven NSCLC: new generation inhibitors and rationale for combination strategies.
Alessandro Russo, Andrés F Cardona, Christian Caglevic, Paolo Manca, Alejandro Ruiz-Patiño, Oscar Arrieta, Christian Rolfo. Transl Lung Cancer Res 2020
3

How selecting best upfront therapy for metastatic disease?-Focus on ROS1-rearranged disease.
Lorenza Landi, Federico Cappuzzo. Transl Lung Cancer Res 2020
0